Quell Therapeutics
Develops engineered CAR-Treg cell therapies for autoimmune disease and organ transplant rejection.
quell-tx.com ↗Why it's here
2019 Syncona-founded spinout of UCL and KCL that raised a $156M Series B and started its CHILL Phase 1/2 trial in March 2026.
source: quell-tx.com- Focus
- Cell Therapy
- Founded
- 2019
- Latest round
- Series B, $156M, Nov 2021
- London office
- 3rd Floor, Translation & Innovation Hub, 84 Wood Lane, Hammersmith and Fulham W12 0BZsource: quell-tx.com
- London presence
- HQsource: kcl.ac.uk
- Investors
- Fidelity Management & Research (lead), Jeito Capital (lead), Ridgeback Capital Investments (lead), SV Health Investors (lead), British Patient Capital, Janus Henderson Investors, Monashee Investment Management, Point72, Syncona, Tekla Capital Managementsource: quell-tx.com
- Nearest station
- White City, 424 m
- Visas
- Licensed visa sponsor, listed as Quell Therapeutics Ltdsource: gov.uk
Verified 6 Oct 2026. How we verify · Suggest a fix
For Quell Therapeutics
Work here? Show you're on the map. Add the badge to your site or README, or share the listing.
<a href="https://londonmempool.co.uk/c/quell-therapeutics"><img src="https://londonmempool.co.uk/badge/quell-therapeutics.svg" alt="Quell Therapeutics is listed on London Mempool" width="357" height="28"></a>
Add ?theme=light to the image URL for light backgrounds.
Same building
3 more companies on the map list this office address.